首页> 美国卫生研究院文献>British Journal of Cancer >Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’

【2h】

Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’

机译：评论 BRAF non-V600E突变对转移性结直肠癌预治疗的抗EGFR单克隆抗体治疗的临床意义：通过综合癌症基因组学（BREAC）研究抗EGFR单克隆抗体的生物标志物研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 British Journal of Cancer
作者
Matthew Dankner; April A. N. Rose;
展开▼
作者单位

展开▼
年(卷),期 2018(118),9
年度 2018
页码 1276–1277
总页数 2
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study [J] . Eiji Shinozaki, Takayuki Yoshino, Kentaro Yamazaki, British Journal of Cancer . 2017,第10期

机译： BRAF 非V600E突变对治疗的转移性结直肠癌患者抗EGFR单克隆抗体的治疗作用的临床意义：基于综合癌症基因组学（BREAC）的抗EGFR单克隆抗体的生物标志物研究研究
2. Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer' [J] . Andrew Rowland, Mafalda M Dias, Michael D Wiese, British Journal of Cancer . 2015,第11期

机译：回复：关于“ BRAF突变的元分析作为抗EGFR单克隆抗体治疗RAS野生型转移性结直肠癌获益的预测生物标志物”的评论
3. BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer:a Meta-analysis [J] . Jia Wei 中国医学科学杂志（英文版） . 2014,第004期

机译：BRAF V600E突变作为转移性结直肠癌中抗EGFR单克隆抗体治疗效果的预测因素：一项荟萃分析
4. A Mathematical Model for Assessing KRAS Mutation Effect on Monoclonal Antibody Treatment of Colorectal Cancer [C] . Sheema Sameen, Roberto Barbuti, Paolo Milazzo, International Conference on Software Engineering and Formal Methods . 2015

机译：评估克拉斯突变对直肠癌单克隆抗体治疗的数学模型
5. Combined use of multiple monoclonal antibodies targeting epidermal growth factor receptor for improved cancer therapeutics. [D] . Kamat, Vishal Gopalkrishna. 2010

机译：多种靶向表皮生长因子受体的单克隆抗体联合使用可改善癌症治疗效果。
6. Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study [O] . Eiji Shinozaki, Takayuki Yoshino, Katsuya Tsuchihara 2018

机译：答复评论 BRAF非V600E突变对抗EGFR单克隆抗体治疗转移性结直肠癌患者的治疗作用的临床意义：综合癌症基因组学（BREAC）研究抗EGFR单克隆抗体的生物标志物研究
7. Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’ [O] . Matthew Dankner, April A. N. Rose 2018

机译：评论对预处理转移性结直肠癌患者抗EGFR单克隆抗体治疗抗EGFR单克隆抗体治疗的临床意义：综合癌症基因组学（BREAC）研究对抗EGFR单克隆抗体的生物标志物研究'

著录项

相似文献

相关主题

期刊订阅